Feasibility of Hepatic T1-Mapping and Extracellular Volume Quantification on Routine Cardiac Magnetic Resonance Imaging in Patients with Infiltrative and Systemic Disorders

Rationale and Objectives: Cardiac magnetic resonance imaging (CMR) is commonly obtained to evaluate for myocardial infiltrative disorders and fibrosis. Pre- and post-Gadolinium contrast T1-mapping sequences are employed to estimate interstitial expansion using extracellular volume fraction (ECV). Given the proximity of the liver to the heart, T1 and ECV quantification of the liver is feasible on CMR. The purpose of this study was to evaluate for hepatic measures of fibrosis and interstitial expansion in patients with amyloidosis or systemic disease on CMR. Materials and Methods: Myocardial and hepatic native T1 values were measured retrospectively using a cardiac short axis modified Look-Locker inversion recovery sequence. Myocardial and hepatic ECV were calculated using pre- and post-contrast T1 and blood pool values according to the following formula: ECV = (Delta(1,T1) myocardium or liver and/or Delta(1/T1) blood)x(1 - hematocrit). Patients were divided into three cohorts by final diagnosis: amyloidosis, systemic disease (e.g. sarcoid, scleroderma), and controls (EF > 50, no ischemia). Results: Of the 135 patients who underwent CMR, 22 had cardiac amyloidosis (age 59.9 +/- 12.6 yrs, 41% female), 20 had systemic disease (age 50.9 +/- 13.4 yrs, 35% female), and 93 were controls (age 49.5 +/- 17.3 yrs, 50% female). Myocardial T1 and ECV values were highest for patients with amyloid, second highest for systemic disease, and least for controls (T1: 1169 +/- 92 vs 1101 +/- 53 vs 1027 +/- 73 ms, p < 0.0001; ECV: 0.47 +/- 0.11 vs 0.31 +/- 0.05 vs 0.27 +/- 0.04, p < 0.0001). Hepatic T1 and ECV were similarly higher in patients with amyloid and systemic disease compared to controls (T1: 646 +/- 101 vs 660 +/- 93 vs 595 +/- 58 ms, p < 0.0001; ECV: 0.38 +/- 0.08 vs 0.37 +/- 0.05 vs 0.31 +/- 0.03, p < 0.0001). There was a positive correlation between hepatic T1 and ECV (R-2 = 0.282, p < 0.0001). No patients had abnormal liver function tests or clinical liver disease. Conclusion: Hepatic ECV quantification on CMR in patients with amyloidosis and systemic disorders is feasible. Further longitudinal investigation regarding detection of early or subclinical liver disease is warranted.